Celgene and Novartis Pharmaceuticals filed suit against Par Pharmaceutical over six patents related to drugs with diminished abuse potential. 11/10, District of New Jersey, 2:2011cv06640.
Access to the full article is currently available to RPX members only. Please contact us if you need further information.
